SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences in March:
TD Cowen 45th Annual Health Care Conference
Presenting on Monday, March 3, 2025, at 9:10 a.m. ET
Leerink Partners Global Biopharma Conference
Presenting on Tuesday, March 11, 2025, at 9:20 a.m. ET
Barclays 27th Annual Global Healthcare Conference
Wednesday, March 12, 2025
Jefferies Biotech on the Beach Summit
Wednesday, March 12, 2025
Live webcasts of the TD Cowen 45th Annual Health Care Conference and Leerink Partners Global Biopharma Conference presentations will be accessible on the Investor page of Travere’s website at www.ir.travere.com/events-presentations. Replays will be available for up to 30 days following each event.
About Travere Therapeutics
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.
Contact:
Last Trade: | US$20.81 |
Daily Change: | 0.73 3.64 |
Daily Volume: | 1,475,343 |
Market Cap: | US$1.810B |
April 29, 2025 April 29, 2025 March 31, 2025 March 17, 2025 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load